PTIXW
Income statement / Annual
Last year (2024), Protagenic Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Protagenic Therapeutics, Inc.'s net income was -$5.53 M.
See Protagenic Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
06/30/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$50.29 K
|
$28.22 K
|
$0.00
|
$0.00
|
$286.00
|
$339.00
|
$347.00
|
$148.00
|
$534.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$28.22 K
|
$0.00
|
$0.00
|
-$286.00
|
-$339.00
|
-$347.00
|
-$148.00
|
-$534.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$3.85 M
|
$3.32 M
|
$1.59 M
|
$1.14 M
|
$699.80 K
|
$807.95 K
|
$881.19 K
|
$717.45 K
|
$417.87 K
|
$464.46
|
| General & Administrative Expenses |
$1.76 M
|
$1.21 M
|
$1.97 M
|
$3.00 M
|
$1.85 M
|
$1.28 M
|
$1.43 M
|
$1.65 M
|
$1.41 M
|
$491.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$115.83 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.76 M
|
$1.18 M
|
$1.97 M
|
$3.00 M
|
$1.85 M
|
$1.28 M
|
$1.43 M
|
$1.65 M
|
$1.30 M
|
$491.00 K
|
| Other Expenses |
$97.36 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$404.17 K
|
-$8.18 K
|
| Operating Expenses |
$5.70 M
|
$4.50 M
|
$3.56 M
|
$4.14 M
|
$2.55 M
|
$2.09 M
|
$2.31 M
|
$2.37 M
|
$1.83 M
|
$491.00 K
|
| Cost And Expenses |
$5.70 M
|
$4.53 M
|
$3.56 M
|
$4.14 M
|
$2.55 M
|
$2.09 M
|
$2.31 M
|
$2.37 M
|
$2.23 M
|
$491.00 K
|
| Interest Income |
$43.47 K
|
$264.48 K
|
$185.79 K
|
$33.21 K
|
$502.00
|
$2.81 K
|
$2.79 K
|
$13.89 K
|
$907.00
|
$0.00
|
| Interest Expense |
$0.00
|
$107.68 K
|
$137.46 K
|
$496.91 K
|
$246.18 K
|
$15.89 K
|
$2.79 K
|
$13.89 K
|
$7.16 K
|
$18.00 K
|
| Depreciation & Amortization |
$50.29 K
|
$28.22 K
|
$30.00
|
$286.00
|
$286.00
|
$339.00
|
$347.00
|
$148.00
|
$534.00
|
$143.00
|
| EBITDA |
-$5.48 M |
-$4.50 M |
-$3.37 M |
-$4.14 M |
-$2.55 M |
-$2.09 M |
-$2.31 M |
-$2.37 M |
-$2.27 M |
-$1.03 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$175.61 K
|
-$474.00 K
|
$2.28 K
|
-$383.00 K
|
$2.88 K
|
$335.22 K
|
-$243.00 K
|
$105.69 K
|
-$42.33 K
|
$1.62 K
|
| Income Before Tax |
-$5.53 M
|
-$5.00 M
|
-$3.56 M
|
-$4.52 M
|
-$2.55 M
|
-$1.75 M
|
-$2.56 M
|
-$2.26 M
|
-$2.28 M
|
-$1.02 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$463.71 K
|
$246.18 K
|
$15.89 K
|
$486.81 K
|
-$106.00 K
|
$440.24 K
|
-$33.00 K
|
| Net Income |
-$5.53 M
|
-$5.00 M
|
-$3.56 M
|
-$4.52 M
|
-$2.80 M
|
-$1.75 M
|
-$2.56 M
|
-$2.26 M
|
-$2.28 M
|
-$476.00 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.13 |
-1.15 |
-0.83 |
-1.24 |
-1.08 |
-0.69 |
-1 |
-0.88 |
-1.72 |
-73.23 |
| EPS Diluted |
-1.13 |
-1.15 |
-0.83 |
-1.24 |
-1 |
-0.69 |
-1 |
-0.88 |
-1.72 |
-73.23 |
| Weighted Average Shares Out |
$4.90 M
|
$4.35 M
|
$4.32 M
|
$3.69 M
|
$2.59 M
|
$2.57 M
|
$2.57 M
|
$2.57 M
|
$1.33 M
|
$118.00 K
|
| Weighted Average Shares Out Diluted |
$4.90 M
|
$4.35 M
|
$4.32 M
|
$3.69 M
|
$2.59 M
|
$2.57 M
|
$2.57 M
|
$2.57 M
|
$1.33 M
|
$118.10 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
